BACKGROUND: : Limited information exists on the prognostic value of genotypic interpretation systems (GISs) for ritonavir-boosted protease inhibitors (PI/rs). We compared PI/r resistance levels ascribed by four GIS and examined their abilities to predict HIV-RNA reductions after starting a PI/r-based regimen (baseline). METHODS: : Data on viraemic (HIV-RNA >; 500 copies/ml) patients starting a PI/r with a baseline resistance test were combined from an observational cohort study (EuroSIDA) and three randomized trials (MaxCmin1; MaxCmin2 and COLATE). The GIS surveyed were ANRS, DMC, REGA and Stanford. Factors associated with HIV-RNA change were identified through censored regression analysis. RESULTS: : We included 744 patients, of whom 67% were PI experienced. At baseline 12-28% (depending on the GIS) patients had a virus with predicted resistance/intermediate resistance to the PI/r initiated. Concordance between GISs on ascribed PI/r resistance levels was moderate: kappa values ranged from 0.01 to 1.00, with the lowest kappas seen for amprenavir. The median (interquartile range) baseline HIV-RNA was 4.4 (3.5-5.1) log10 and was reduced by 2.2 (2.1-2.3) log10 12 (9-13) weeks after baseline. GIS consistently showed greater HIV-RNA reductions as the ascribed level of sensitivity to the PI/r increased. Conversely, the number of other active drugs in the rest of the regimen, according to each GIS did not predict HIV-RNA reductions consistently. CONCLUSION: : Despite large variations in how GIS classify HIV susceptibility to PI/r, all GIS predicted HIV-RNA reductions of a similar magnitude. The ascribed level of susceptibility to other drugs in the regimen did not predict HIV-RNA decline.
RCT Entities:
BACKGROUND: : Limited information exists on the prognostic value of genotypic interpretation systems (GISs) for ritonavir-boosted protease inhibitors (PI/rs). We compared PI/r resistance levels ascribed by four GIS and examined their abilities to predict HIV-RNA reductions after starting a PI/r-based regimen (baseline). METHODS: : Data on viraemic (HIV-RNA > 500 copies/ml) patients starting a PI/r with a baseline resistance test were combined from an observational cohort study (EuroSIDA) and three randomized trials (MaxCmin1; MaxCmin2 and COLATE). The GIS surveyed were ANRS, DMC, REGA and Stanford. Factors associated with HIV-RNA change were identified through censored regression analysis. RESULTS: : We included 744 patients, of whom 67% were PI experienced. At baseline 12-28% (depending on the GIS) patients had a virus with predicted resistance/intermediate resistance to the PI/r initiated. Concordance between GISs on ascribed PI/r resistance levels was moderate: kappa values ranged from 0.01 to 1.00, with the lowest kappas seen for amprenavir. The median (interquartile range) baseline HIV-RNA was 4.4 (3.5-5.1) log10 and was reduced by 2.2 (2.1-2.3) log10 12 (9-13) weeks after baseline. GIS consistently showed greater HIV-RNA reductions as the ascribed level of sensitivity to the PI/r increased. Conversely, the number of other active drugs in the rest of the regimen, according to each GIS did not predict HIV-RNA reductions consistently. CONCLUSION: : Despite large variations in how GIS classify HIV susceptibility to PI/r, all GIS predicted HIV-RNA reductions of a similar magnitude. The ascribed level of susceptibility to other drugs in the regimen did not predict HIV-RNA decline.
Authors: Philip Grant; Eric C Wong; Richard Rode; Robert Shafer; Andrea De Luca; Jeffrey Nadler; Trevor Hawkins; Calvin Cohen; Robert Harrington; Dale Kempf; Andrew Zolopa Journal: Antimicrob Agents Chemother Date: 2008-08-18 Impact factor: 5.191
Authors: G Sterrantino; M Zaccarelli; G Colao; F Baldanti; S Di Giambenedetto; T Carli; F Maggiolo; M Zazzi Journal: Infection Date: 2012-01-12 Impact factor: 3.553
Authors: Beverly E Sha; Camlin Tierney; Susan E Cohn; Xin Sun; Robert W Coombs; Lisa M Frenkel; Spyros A Kalams; Francesca T Aweeka; Barbara Bastow; Arlene Bardeguez; Anne Kmack; Alice Stek Journal: HIV Clin Trials Date: 2011 Jan-Feb
Authors: Dineke Frentz; Charles A B Boucher; Matthias Assel; Andrea De Luca; Massimiliano Fabbiani; Francesca Incardona; Pieter Libin; Nino Manca; Viktor Müller; Breanndán O Nualláin; Roger Paredes; Mattia Prosperi; Eugenia Quiros-Roldan; Lidia Ruiz; Peter M A Sloot; Carlo Torti; Anne-Mieke Vandamme; Kristel Van Laethem; Maurizio Zazzi; David A M C van de Vijver Journal: PLoS One Date: 2010-07-09 Impact factor: 3.240
Authors: Soo-Yon Rhee; W Jeffrey Fessel; Tommy F Liu; Natalia M Marlowe; Charles M Rowland; Richard A Rode; Anne-Mieke Vandamme; Kristel Van Laethem; Françoise Brun-Vezinet; Vincent Calvez; Jonathan Taylor; Leo Hurley; Michael Horberg; Robert W Shafer Journal: J Infect Dis Date: 2009-08-01 Impact factor: 5.226
Authors: Soo-Yon Rhee; Jose Luis Blanco; Tommy F Liu; Iñaki Pere; Rolf Kaiser; Maurizio Zazzi; Francesca Incardona; William Towner; Josep Maria Gatell; Andrea De Luca; W Jeffrey Fessel; Robert W Shafer Journal: AIDS Res Ther Date: 2012-05-03 Impact factor: 2.250
Authors: Sally Land; Philip Cunningham; Jialun Zhou; Kevin Frost; David Katzenstein; Rami Kantor; Yi-Ming Arthur Chen; Shinichi Oka; Allison DeLong; David Sayer; Jeffery Smith; Elizabeth M Dax; Matthew Law Journal: J Virol Methods Date: 2009-03-26 Impact factor: 2.623